Study backs safety of new pneumococcal vaccine

05/24/2013 | United Press International

A U.S. study showed that the new 13-valent pneumococcal conjugate vaccine is as safe as the previously used 7-valent pneumococcal conjugate vaccine. Kaiser Permanente researchers compared the number of rare adverse events linked to the new and old vaccines and found that those who received the PCV13 vaccine were no more likely to experience any serious adverse events than those who got the PCV7 vaccine.

View Full Article in:

United Press International

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA